IUL.F IMMUCELL CORP. DL-10
- Market cap
- EUR 82.2M
- P/E
- 150.8x
- P/B
- 3.04x
- ROE
- 24.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IUL.F undervalued?
Graham numberThe Graham number of IMMUCELL CORP. DL-10 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMMUCELL CORP. DL-10 fundamental analysis
No fundamental analysis for IMMUCELL CORP. DL-10 yet.
IMMUCELL CORP. DL-10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMMUCELL CORP. DL-10
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment o…
Full company profileIMMUCELL CORP. DL-10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IMMUCELL CORP. DL-10 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 19.2M | 18.6M | 17.5M | 26.5M | 27.6M | 35.1M |
| Gross Profit | 8.66M | 7.65M | 3.87M | 7.94M | 11.4M | 14.2M |
| Operating Income | 257K | -2.30M | -5.75M | -1.64M | 1.65M | 7.81M |
| EBITDA | - | 350K | -2.60M | 1.07M | 2.14M | 10.0M |
| Net Income | -78.3K | -2.49M | -5.77M | -2.16M | -1.04M | 7.55M |
| EPS | -0.01 | -0.32 | -0.75 | -0.24 | -0.11 | 0.83 |
| Balance Sheet | ||||||
| Total Assets | 44.5M | 44.9M | 43.8M | 45.1M | 42.5M | 46.6M |
| Total Liabilities | 11.9M | 14.5M | 18.8M | 17.6M | 15.5M | 15.3M |
| Shareholders' Equity | 32.6M | 30.4M | 25.0M | 27.5M | 27.1M | 31.4M |
| Cash & Short-term Investments | 10.2M | 5.79M | 979K | 3.76M | 3.81M | 8.86M |
| Cash Flow | ||||||
| Operating Cash Flow | 954K | -1.54M | -4.67M | 358K | 2.48M | 13.2M |
| Capital Expenditure | 2.61M | 3.98M | 1.89M | 466K | 1.25M | 1.82M |
| Free Cash Flow | -1.65M | -5.52M | -6.57M | -108K | 1.22M | 11.4M |
| Ratios | ||||||
| ROE | -0.2% | -8.2% | -23.1% | -7.8% | -3.8% | 24.1% |
| ROA | -0.2% | -5.6% | -13.2% | -4.8% | -2.4% | 16.2% |
| Net Profit Margin | -0.4% | -13.4% | -33.1% | -8.1% | -3.8% | 21.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IMMUCELL CORP. DL-10 dividends
IMMUCELL CORP. DL-10 has not paid dividends in the last 5 fiscal years.
Who owns IMMUCELL CORP. DL-10
- Insiders 32.09%
- Institutions 20.50%
- Public & others 47.41%
- Shares outstanding 9.08M
- Free float 6.03M
IMMUCELL CORP. DL-10 company profile
- Company name
- IMMUCELL CORP. DL-10
- Ticker
- IUL.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- 56 Evergreen Drive, Portland, ME, United States, 04103
- Phone
- 207 878 2770
- Website
- immucell.com
About IMMUCELL CORP. DL-10
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
IMMUCELL CORP. DL-10 management
6- Mr. Paul F. Olivier Te BoekhorstPresident, CEO & Director · born 1972
- Mr. Timothy C. FioriCFO, Secretary & Treasurer · born 1979
- Ms. Bobbi Jo BrockmannSenior Vice President of Sales & Marketing · born 1977
- Ms. Elizabeth S. ToothakerDirector of Finance & Administration and Controller
- Mr. A. Gustavo ScaffaSenior Director of Quality
- John W. ZinckgrafDirector of Product Development